Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Michael B. Wallace

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6446-5785; OpenAlex author ID A5010559287, A5079578428, A5123236115, A5135252035; NIH RePORTER profile ID 7017555. Sources: ClinicalTrials.gov.

Their work

Papers
40 (first author 6, last author 11)
Trials
5 (principal investigator on 5)
Grants
1
Labs led
1
Collaborators
137
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: 1 trial · 2009: 1 trial · 2010: 1 trial · 2011: 1 grant · 2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 1 trial · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: 8 papers · 2026: 5 papers

Papers 40

  1. Longitudinal body composition changes distinguish pancreatic ductal adenocarcinoma from controls in a pre-diagnostic CT cohort. Co-author DOI 10.1016/j.pan.2026.09.008↗
  2. An Analysis of the Clinical Burden and Economic Costs of Venous Thromboembolism During Inpatient Admissions for Pancreatic Cancer in the United States. Co-author DOI 10.1177/10499091251341453↗
  3. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ajg.0000000000003896↗
  4. Early Detection of Pancreatic Ductal Adenocarcinoma through Layered Multimodal Risk Enrichment of Routine Clinical Data Co-author DOI 10.21203/rs.3.rs-11265358/v1↗
  5. Cost-Effectiveness and Clinical Utility of Pancreatic Cancer Non-Invasive Test in New-Onset Diabetes. Last author DOI 10.2147/ceor.s577796↗
  6. AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication. Co-author DOI 10.1007/s00261-024-04775-x↗
  7. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  8. Early-onset pancreatic cancer and associated metabolic risk factors in the Middle East and North Africa: A 20-year analysis of the Global Burden of Disease Stu… Co-author DOI 10.1007/s12664-024-01626-x↗
  9. Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.bpg.2025.101974↗
  10. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Co-author DOI 10.1016/j.cgh.2024.07.048↗
  11. Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases. Co-author DOI 10.1097/mpa.0000000000002517↗
  12. Cost-Effectiveness of a Risk-Based Pancreatic Cancer Early Detection Strategy in New-Onset Diabetes Patients Using a Blood-Based, Non-Invasive Test – An Econom… Last author DOI 10.1101/2025.11.12.25340092↗
  13. Cyst-X: AI-Powered Pancreatic Cancer Risk Prediction from Multicenter MRI in Centralized and Federated Learning Last author DOI 10.21203/rs.3.rs-7236860/v1↗
  14. Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2024.03.038↗
  15. The Global Burden of Early-Onset Pancreatic Cancer and Its Risk Factors: A Perspective From Global Burden of Disease Study 2019. Co-author DOI 10.1097/mpa.0000000000002331↗
  16. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op.23.00447↗
  17. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  18. Identification of individuals at high-risk for pancreatic cancer using a digital patient-input tool combining family cancer history screening and new-onset dia… Last author DOI 10.1016/j.pmedr.2023.102110↗
  19. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  20. Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Co-author DOI 10.3390/cancers15041235↗
  21. Prevalence, features, and explanations of missed and misinterpreted pancreatic cancer on imaging: a matched case-control study. Co-author DOI 10.1007/s00261-022-03671-6↗
  22. Hereditary pancreatic cancer. First author DOI 10.1016/j.bpg.2021.101783↗
  23. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  24. Pancreatic steatosis on computed tomography is an early imaging feature of pre-diagnostic pancreatic cancer: A preliminary study in overweight patients. Co-author DOI 10.1016/j.pan.2021.01.003↗
  25. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  26. Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomi… Last author DOI 10.1055/a-1223-2171↗
  27. The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004-2013: A SEER Analysis. Last author DOI 10.1080/07357907.2021.1888386↗
  28. A 3-Decade Analysis of Pancreatic Adenocarcinoma After Solid Organ Transplant. Co-author DOI 10.1097/mpa.0000000000001722↗
  29. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  30. Early detection and imaging strategies to reveal and target developing pancreatic cancer First author DOI 10.1080/14737140.2020.1720654↗
  31. Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies. Last author DOI 10.1016/j.cgh.2018.04.065↗
  32. Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis. Last author DOI 10.1097/mpa.0000000000001268↗
  33. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. First author DOI 10.1089/pancan.2018.0011↗
  34. Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer. First author DOI 10.3390/cancers10020054↗
  35. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. Last author DOI 10.1136/gutjnl-2014-307475↗
  36. Polarization gating spectroscopy of normal-appearing duodenal mucosa to detect pancreatic cancer. Last author DOI 10.1016/j.gie.2014.03.031↗
  37. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. First author DOI 10.2174/1566524013666131217112921↗
  38. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. Co-author DOI 10.7150/jca.10094↗
  39. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needl… Last author DOI 10.1055/s-0033-1344216↗
  40. The role of endoscopic ultrasonography in the diagnosis and management of pancreatic cancer. First author DOI 10.1016/j.gtc.2011.12.014↗

Trials 5

  1. Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle Principal investigator NCT02678442↗
  2. Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer Principal investigator NCT01015820↗
  3. Confocal Endomicroscopy of Pancreatic InVivo Principal investigator NCT01035008↗
  4. Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer Principal investigator NCT00826982↗
  5. Randomized Trial of EUS Neurolysis in Pancreas Cancer Principal investigator NCT00279292↗

Grants 1

  1. Fusion gene mutations as biomarkers of pancreatic cancer lymph node metastases R21CA151160↗

Closest collaborators

The 25 strongest of 137 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Derk C.F. Klatte · 10 shared papers, 2022–2026 · strength 2.30
  2. Yan Bi · 9 shared papers, 2021–2026 · strength 1.96
  3. Monique Esther van Leerdam · 8 shared papers, 2022–2026 · strength 1.92
  4. Jeanin Elise van Hooft · 9 shared papers, 2021–2026 · strength 1.88
  5. Massimo Raimondo · 12 shared papers, 2013–2026 · strength 1.41
  6. Aleksander M. Bogdanski · 5 shared papers, 2025–2026 · strength 1.32
  7. Adrian Vilalta · 2 shared papers, 2025–2026 · strength 0.93
  8. Candice W. Bolan · 5 shared papers, 2018–2025 · strength 0.77
  9. Sanne A.M. Hoogenboom · 4 shared papers, 2021–2025 · strength 0.70
  10. Che G. Ngufor · 2 shared papers, 2026 · strength 0.60
  11. Koen J.H. Wijsman · 2 shared papers, 2026 · strength 0.59
  12. Juan E. Corral · 4 shared papers, 2019–2021 · strength 0.54
  13. Karn Wijarnpreecha · 3 shared papers, 2021–2025 · strength 0.54
  14. Megan M.L. Engels · 3 shared papers, 2022–2025 · strength 0.54
  15. Frank Lukens · 2 shared papers, 2025–2026 · strength 0.53
  16. Douglas L. Riegert‐Johnson · 3 shared papers, 2019–2025 · strength 0.52
  17. Marco J. Bruno · 3 shared papers, 2019–2025 · strength 0.51
  18. Pojsakorn Danpanichkul · 2 shared papers, 2024–2025 · strength 0.42
  19. Pujan Kandel · 3 shared papers, 2018–2021 · strength 0.39
  20. Victoria Gómez · 3 shared papers, 2018–2025 · strength 0.39
  21. Osayande Osagiede · 1 shared paper, 2026 · strength 0.36
  22. Pilar Acedo · 1 shared paper, 2025 · strength 0.33
  23. Yan Bi · 1 shared paper, 2026 · strength 0.32
  24. John Andrew Stauffer · 4 shared papers, 2013–2021 · strength 0.31
  25. Bhaumik S. Brahmbhatt · 2 shared papers, 2021–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.